X, to you, for Good I'm and few you months Thank for a you a joining to Eton's year, advancement talking strategy: business critical we us forward X-pillar with our everyone, thank and of have busy organic afternoon, in products; It's history. transactions been today last at exciting talking growth about pipeline and existing internal development David. us, X, portfolio; such all of Throughout of accelerate our X, and growth. today. looking been moment value-creating the
X I'm pleased to pillars. these of all major we have in report that progress delivered
producing existing growth. First, attractive XXth organization our growth products, quarter our commercial of our continues deliver product to straight from sequential revenue organic
and February PDUFA transformational on development signing opportunity our a accepted asset company. announced review ET-XXX, front, was of lastly, third month, represented quarter for a the agreement important milestone acquire brought XX FDA pipeline the we which the to a Increlex the product, And purchase for business the for last Secondly, critical an date. by which assigned
these accomplishments team's to I months, in QX few our these of to start I'll look discussing and over forward I cannot detail. of more achieve work with proud the each be results. hard our results last more
product in mentioned, was third reach we to reach that sales. continues I As increases GAAP to net of XX% quarter. We fourth up were so our pleased able The to the quarter us quarter previously am schedule. and carglumic GAAP in income of growth by both it said by and sales year-over-year Product allowed sales the driven positive strong this strong achieve be record of we ahead income to one goal net delivered Alkindi quarter I were Sprinkle acid. year, another the
major development and many milestone the of for company. often GAAP worth investment the world, any activities. is a pharmaceutical Reaching revenue of In profitability earnings in are years result
regulatory of is case spent are Our more and building commercial and labor different after the infrastructure the on years activities, see drug our hard development to we starting opportunities. our come to years out business ahead. evaluating no much development as expect fruits months and working many we in
at always Profitability will a been part Eton. strategy and of our has always central be
not unprofitable growth. are We chasing in interested
up while in This flow minimizing closely approach our now revenue tirelessly allowed spending, monitoring to have maintaining pipeline, income a cash to has produce and a worked growth, cost structure. By we have We quarter. XXXX disease able while GAAP us attractive this attractive shareholders. breakeven to dilution been reach disciplined positive rare portfolio build and Eton's to
the to from we far profitability milestone for have finished. but this pleased company, very are are reached We critical
deliver on we Increlex and expect the are expected ET-XXX additions our think top In with existing early story growth about fact, I growth from we our XXXX. in excited continued of are what of stages to very portfolio, of the we in
that with materialize primary perfectly EMA about Ipsen I that X we last of growth that approved and have for to year. this And product endocrinology pediatric we deficiency. Increlex factor an an the asset with pleased mentioned had severe acquiring I call, a it we the our treatment product purchase announced purchase agreement were commercial attractive for last insulin-like our signed was see During optimistic fits month biologic focus. asset larger of is It FDA Increlex. is an when
undertreated. With pediatric closes. the presence close of awareness transaction to able and more to for an hand both share endocrinology and we our expansion expectations to this this can The and credit of community, we underdiagnosed finance relationships condition, cash and we the is of existing strong end to year, on with transaction entirely will acquisition our in after believe our raise facility. be about towards appears which be plan expected and the product We the
In order expected near-term of are launch as of an Increlex addition our to force the in help expansion we ET-XXX, and XXXX. as well sales of realignment support planning the
additional us current metabolic portfolio. X our on disease Our rare Carglumic specialists focused Acid, potential exclusively promoting XX sales focus entire split allow PKU believe X to and units into and specialists our ET-XXX will realignment will Nitisinone. maximize the portfolio, Increlex revenue this and GOLIKE, pediatric force separate approximately with Alkindi Sprinkle be will Betaine product promoting on endocrinology, We of
The than our roughly and product Sprinkle of product trajectory we delivered growth Now we year-over-year to and we long growth believe would runway on results. through with rate, expect next the target continue product-specific revenue a growth Alkindi of be the the XX% XXXX, Despite and it. yet grow even is of current that to accelerate ET-XXX with to patent higher discontinuation XX% and like, ahead franchise's a population year. patients active to protection launch has rate the converted. the has
count can is confident the an level. that products higher than current patient that combined the active significantly reach We remain
portfolio, revenue Regarding growth, GOLIKE strong earlier our PKU acquisition saw driven this nice of to our we quarter by Acid. since interest another Carglumic primarily metabolic see continues year.
plus GoLike growth year in metabolic lead franchise anticipated an increase we second next fully referrals force the to believe seen of promotional a reengaged in in significant sales the tyrosinemia we this quarter, have since having will activities We in XXXX. and launch that dedicated early
on to our candidates. Moving pipeline
During a of exciting proprietary assigned ET-XXX, date has drug FDA PDUFA's the formulation application XXXX. hydrocortisone February news the and for received quarter, oral that a solution patented action of accepted we new the XX, our
more are going X now that it months is of well. believe application, the into we the review than and We
have we manufacturing scheduled result, this approval. launch after have a of commercial shortly the available initial enable As to the will us inventory This potential FDA later product quarter.
all campaign. aspects Our at marketing launch team preparation, our hard including on is other work of
to will In us should relatively this received by has readout to that important NDA now this end anticipate we XXXX. Trademark the end been addition, products study data study week, If the where quickly, our file allow near be the pivotal U.S. IP year. our completed Patent a ET-XXX, strengthening On of first granted in we and on initiated, further initial having this us good the the news for successful, Office second this quarter protection of patent and last ET-XXX, an product.
market early pediatric very planned, ET-XXX endocrinology As for pediatric you with are may pilot this are our first and about as year, the so optimistic as bolstering this recall, XXXX. now a the ET-XXX. be study. commercial pivotal everything in about of as we quarter ran we And be passed study further part endocrinology the goes Increlex on presence, fourth previously the outcome first will product our prospects of we and of could If the excited
are acquisition. all executing transformational for and we of financial quarter positioned candidates resulted the As our you've making delivering entering I fronts. pipeline not we more how net income, stellar in am on excited I results a seen executing another our be from of XXXX. results, that proud are advancing GAAP team progress could for
this disease additional and our reaching to We ET-XXX near-term of have products XXXX. clear the with path XX Increlex hope in we way potential to all launches With long-term well of rare are for progress, ET-XXX, X. on products goals our commercial is That commercial and have company. we to a X
$XXX revenue, million should expected the term. the achieve launches this in of and put reaching in a path near Increlex both on ET-XXX to trajectory us Secondly,
in $X We all believe developing for this new and execute continuing a of on goals we and we're If and Eton. are launching shareholder coming our market years. these billion in products X we big and value-creating things to reaching support, ahead on reach can our we Thirdly, cap. the first strategy believe continue appreciate successful milestone acquisitions delivering to
the I'll turn that, With James? Chief discuss Financial financials. over it to Officer, to James, our
